- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
FDA approves new microcannula
The Food and Drug Administration has approved Cosmofrance’s Dermasculpt, a flexible blunt-tip microcannula for non-bruising and virtually painless cosmetic injections, Medical News Today reports.
Miami Beach, Fla. - The Food and Drug Administration has approved Cosmofrance’s Dermasculpt, a flexible blunt-tip microcannula for non-bruising and virtually painless cosmetic injections, Medical News Today reports.
According to Cosmofrance, based here, Dermasculpt microcannulas are used to administer facial fillers in conjunction with the company’s Skin Sculpting Technique (SST). The mechanical stimulation of fibroblast generates new collagen triggered by the microcannula’s back-and-forth movement.
The company says the main benefits of the SST using Dermasculpt microcannulas are that there is virtually no bruising, considerably less pain, wider coverage due to single point of entry, and production of new collagen.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
